FindTrial
Sign In

Effect of Dexmedetomidine on POCD and the expression of HMGB1, RAGEmRNA in peripheral blood in eldly hip or knee replacement surgery patients

Effect of Dexmedetomidine on POCD and the expression of HMGB1, RAGEmRNA in peripheral blood in eldly hip or knee replacement surgery patients

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-16008122
Enrollment
Unknown
Registered
2016-03-20
Start date
2016-03-20
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postoperative cognitive dysfunction

Interventions

DEX:a loading dosage of dexmedetomidine (0.8 ug/Kg) was infused introvenously 15 min before anesthesia and followed continously at 1 ug/Kg/h till the ending of surgery
control group:saline

Sponsors

Qingdao City Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to No maximum

Inclusion criteria

Inclusion criteria: aged >=65 years, ASA I-II

Exclusion criteria

Exclusion criteria: cognitive dysfunction, heart, cerebral vascular accident, severe hypertension, malignant arrhythmia, organ disfuction, long-term use of sedative drugs

Design outcomes

Primary

MeasureTime frame
incidence of POCD;HMGB1;RAGEmRNA;NF-kB;—

Countries

China

Contacts

Public ContactMa Yufeng

Qingdao City Hospital

myf5818@126.com+86 18613626826

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026